Apps

Sickle Cell Gene Therapies Approved as Senegal Makes Local Generic Drug — 20hSenegal's Teranga Pharma launched local generic sickle cell drug Drepaf in November 2025 at up to one-third import prices; Africa holds nearly 80% of global cases.

Marcus Bell This local generic should finally let more African families afford treatment without relying on expensive imports.

Jelly Roll Weighs Music Future, Seeks God’s Direction — 4dJelly Roll says he may walk away from music to follow God’s direction, planning a hiatus and saying he’d do something entirely different if that’s what God wants. His reflections come after a year of major career highs, including Grammys and Grand Ole Opry induction, alongside personal changes like divorce, sobriety, and ongoing therapy as he seeks clarity for his next path.

Paralyzed Athletics Prospect Lasko Leaves Rehabilitation Hospital — 2dAthletics minor league prospect Ryan Lasko, who was paralyzed in an outfield collision in late June, has been released from the Kessler Institute for Rehabilitation and will continue his recovery at home in New Jersey with outpatient therapy. The 24-year-old Rutgers alum fractured the C6 and C7 vertebrae, is gradually regaining sensation, and remains under strong support from teammates, staff, and his family as he begins this next phase.

Women’s Testosterone Prescriptions Rise 146%, FDA Review Planned — 3dThe FDA is reviewing the evidence on testosterone therapy for menopausal women as off-label use rises without an approved product, amid safety concerns and calls for standardized dosing. Meanwhile, prescriptions have surged, but patients face pharmacy delays and coverage gaps, with medical groups limiting use to women with hypoactive sexual desire disorder and researchers preparing a public workshop to assess safety and efficacy.

Longevity Interest Spans Health, Medicine, InvestmentHealth — 5dExperts caution that longevity should be defined by reducing risks of cardiovascular, metabolic, cancer and cognitive diseases through comprehensive testing and personalized plans, not merely chasing arbitrary biological age scores. The conversation across clinics, media voices and investors now spans practical skin- and device-based improvements, measured prevention through the Silent Decade framework, and bold biotech funding aimed at replacement therapies and long-term durability.

FDA Extends Exelixis Drug Review to March 2027 — Sep 11, 2026The FDA has extended Exelixis' NDA review for zanzalintinib in combination with atezolizumab/Tecentriq for metastatic colorectal cancer by three months, moving the action date to March 3, 2027 after updated safety and efficacy data were deemed a major amendment. The development of zanzalintinib as a next-generation cancer therapy continues, with the delay potentially impacting timelines for patients, investors, and partners awaiting a decision.

Nicole Hardy The FDA's move to examine the new safety data more closely makes sense, though it will likely delay any benefits for those counting on the combination therapy.

AstraZeneca Breast Cancer Trial Misses Key Goal — 6dAstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

Marcus Bell It's frustrating the overall trial missed but good the ESR1 group still saw real benefit from the drug.

Cellectis Exits Two CAR-T Programs, Advances Gene Editing — 4dCellectis announced a strategic transformation to become an in vivo gene editing company, shifting resources to two lead programs HEAL-101 and HEAL-201 for severe dyslipidemias and exiting lasme-cel and eti-cel to extend its cash runway into the second half of 2028, while realigning its operating model around the in vivo pipeline. Phase 1 data are planned for HEAL-101 in the second half of 2027 and for HEAL-201 in the first half of 2028, with ongoing cell therapy partnerships and a September 14 conference call to discuss updates.

Dana Whitfield Exiting the CAR-T candidates to reach 2028 cash runway is understandable but leaves them with pretty distant phase 1 readouts.

Lilly Plans $2.88B Merida Autoimmune AcquisitionBusiness — Sep 3, 2026Eli Lilly is rapidly expanding beyond its obesity-and-diabetes blockbuster lineup, striking two multi-deal paths: a $2.875 billion-plus acquisition of Merida Biosciences to broaden its autoimmune and antibody-directed therapies, and a $3.83 billion spree to acquire three biotech firms—Curevo, LimmaTech Biologics, and Vaccine Company—to build a broader vaccine and infectious-disease pipeline. The moves underscore a strategy to diversify growth into immunology, infectious diseases, and autoantibody therapies while managing revenue risk from reliance on a small number of weight‑loss drugs.

Novartis Phase 3 Pelacarsen Trial Misses Cardiovascular Endpoint — Sep 5, 2026Novartis reported that the Phase III Lp(a)HORIZON trial did not meet its primary endpoint, showing that lowering Lp(a) with pelacarsen reduced levels but did not significantly reduce cardiovascular events in approximately 8,000 patients on guideline-directed therapy; the company said full data will be presented at a future medical congress. Meanwhile, Royalty Pharma outlined its financial stance on the pelacarsen investment, noting the trial’s failure won’t derail its recovery of invested funds and that royalties on Spinraza remain a key part of its portfolio as it pursues its 2030 receipts target, with Ionis royalties potentially reverting after a defined cap. The developments reflect a broader scientific and market reevaluation of Lp(a)-targeted therapies and their commercial prospects.

Jared Kim Wonder how many other Lp(a) drugs in the pipeline just got a lot riskier to fund after this readout.

FDA Approves Rasonque for Metastatic PDAC; Price Concerns — Aug 26, 2026The FDA approved Revolution Medicines' pancreatic cancer drug daraxonrasib, sold as Rasonque, the first therapy to target a genetic driver of the disease. In a trial of advanced/metastatic pancreatic cancer, median overall survival reached 13.2 months versus 6.7 with chemotherapy, signaling a potentially transformative option for patients who have received prior therapy.

Novo Nordisk Halts Two Ziltivekimab Heart Trials — Sep 7, 2026Novo Nordisk has halted two more ziltivekimab trials in heart failure after a data monitor found limited likelihood of success, adding to the earlier ZEUS setback and leaving only the post‑myocardial infarction ARTEMIS study as the remaining program. A separate post‑MI study is continuing with results expected in early 2027, underscoring ongoing challenges for inflammation‑targeting cardiovascular therapies.

Rachel Meyers Kind of telling that they're still holding onto that one post-MI study though. Guess we'll see if there's a specific subgroup where this actually works.

Bristol Myers exits Cellares deal, capacity doubt — Aug 25, 2026Bristol Myers Squibb has ended its partnership with cell therapy manufacturer Cellares, raising questions about standardized production capacity for CAR‑T and forcing a reevaluation of forecasting and capacity planning. In the wake of the deal termination, Cellares is restructuring and cutting jobs as it absorbs the loss of a major customer, underscoring fragility in automated cell therapy manufacturing ecosystems.

Therapy Chicken Becomes Fan Favorite for Residents at Assisted Living Center: 'She's So Sweet'Reporting — May 28, 2022When you think of a “therapy animal,” you probably immediately envision a dog. There also are a few standouts you might have seen in the therapy, service or emotional-support animal world: potty-trained miniature horses…

Sandwich-Generation Families Navigate Alzheimer’s Home CareHealth — Sep 9, 2026Personal narratives from caregivers like Eleyna caring for her mother with dementia, Ty Lewis tending to her mother Gertrude at home, and other family members show how families adapt routines, music therapy, and online support to manage end-stage Alzheimer’s while raising children. These accounts highlight the emotional toll, the decision to age-in-place, and the sense of community built around caregiving, with caregivers emphasizing life together and purpose amid a terminal diagnosis.

Brandi Glanville details 18-hour daily IV regimen amid unexplained health battle — Sep 7, 2026Brandi Glanville has revealed that she spends about 18 hours a day on at-home IV therapy, with a nurse visiting for several hours, while her ongoing facial health issues and treatment schedule have left her very thin and affecting her appetite. She has been sharing intimate, behind-the-scenes glimpses of the demanding regimen, including imipenem infusions, as she continues to seek answers about her health.

Ascelia Completes FDA Meeting on OrviglanceHealth — Sep 8, 2026Biopharma firms report a mix of regulatory progress: Ascelia Pharma advances its Orviglance NDA with an FDA Type A meeting held and minutes due in about 30 days, while AstraZeneca secures FDA approval for Etcamah (camizestrant) after an advisory panel opposed it earlier, signaling a potential shift in benefit-risk assessment. Ascletis Pharma launches a US Phase I trial for ASC36 obesity drug under an IND, highlighting ongoing development in metabolism therapies alongside expectations of further data and pricing implications for investors.

ABA Therapy Maps 4,206 Providers NationwideHealth — Aug 27, 2026Top ABA Therapy has cataloged 4,206 ABA provider locations across 46 states and DC, linked to 2,467 provider organizations, and publishes 291 city pages and 47 state pages with a three-provider threshold to avoid thin listings, to aid families researching autism services. Florida and Texas are the largest footprints, and the directory emphasizes data backed by provider records and the NPPES registry while omitting unlabeled paid placements from organic results.

Joe Biden Reportedly Undergoing Radiation Therapy To Treat Cancer — Oct 11, 2025Former President Joe Biden is receiving radiation therapy and hormone treatment as he battles prostate cancer, according to multiple reports. Biden, 82, is responding to treatment and doing well, CBS News reported . The…

Jonathan Turley Sees One Great Irony In Colorado’s Ban On Conversion Therapy — Apr 1, 2026George Washington University law professor Jonathan Turley pointed out Tuesday the irony surrounding Colorado’s legal battles over conversion therapy, calling the state’s actions a surprising boon for free speech…

Stolen Florida Therapy Horse Found Slaughtered for Its MeatReporting — Feb 18, 2024Three stolen horses, including a cognitive health therapy animal, were found slaughtered in a remote field on Friday in rural South Miami-Dade County. Detective Alvaro Zabaleta, of the Miami-Dade Police Department, said…

FDA approves Ionis' Zanvastro as first treatment for rare Alexander disease — Sep 3, 2026The FDA approved Zanvastro (zilganersen) from Ionis as the first disease-modifying therapy for Alexander disease, a rare GFAP-related brain disorder, for adults and children. The intrathecal antisense oligonucleotide lowers abnormal GFAP protein and trials showed stabilization or improvement in motor function with a favorable safety profile, though administration requires specialized settings.

Elena Vasquez Intrathecal delivery is going to be a barrier for a lot of families depending on where they live. Access to specialized centers matters just as much as the approval itself.

Probiotics Revive Heat-Stressed Red Sea Corals — Sep 3, 2026A field study in the central Red Sea during a 2022 heatwave found that both live probiotic and inactivated postbiotic treatments improved the health of corals under thermal stress, demonstrating that microbial therapies can work outside laboratories. The research highlights the practical scaling advantages of postbiotics, such as longer shelf life and easier storage, which could facilitate broader deployment to protect coral reefs.

Biden Admin Cut Big Check To Activists Using Schools As Recruiting Grounds For LGBT ‘Family Therapy’ Program — Dec 7, 2024A Michigan group received federal funds for a “family therapy” program that instructs parents to affirm their child’s gender confusion — and enlists public school districts in the effort. A nearly $1.3 million federal…